ATE298578T1 - Lipid a-analoge enthaltende injektionen und verfahren zu deren herstellung - Google Patents

Lipid a-analoge enthaltende injektionen und verfahren zu deren herstellung

Info

Publication number
ATE298578T1
ATE298578T1 AT97929518T AT97929518T ATE298578T1 AT E298578 T1 ATE298578 T1 AT E298578T1 AT 97929518 T AT97929518 T AT 97929518T AT 97929518 T AT97929518 T AT 97929518T AT E298578 T1 ATE298578 T1 AT E298578T1
Authority
AT
Austria
Prior art keywords
analogues
production
containing lipid
injections containing
lipid
Prior art date
Application number
AT97929518T
Other languages
English (en)
Inventor
Yasuyuki Asai
Katsumi Onai
Kazuhide Ashizawa
Kiyoshi Iwamoto
Yasuo Ishibashi
Sumio Watanabe
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Application granted granted Critical
Publication of ATE298578T1 publication Critical patent/ATE298578T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT97929518T 1996-07-03 1997-07-03 Lipid a-analoge enthaltende injektionen und verfahren zu deren herstellung ATE298578T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP17361596 1996-07-03
PCT/JP1997/002316 WO1998001139A1 (en) 1996-07-03 1997-07-03 Injections containing lipid a analogues and process for the preparation thereof

Publications (1)

Publication Number Publication Date
ATE298578T1 true ATE298578T1 (de) 2005-07-15

Family

ID=15963903

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97929518T ATE298578T1 (de) 1996-07-03 1997-07-03 Lipid a-analoge enthaltende injektionen und verfahren zu deren herstellung

Country Status (9)

Country Link
US (1) US6235724B1 (de)
EP (1) EP0909562B1 (de)
CN (1) CN1150001C (de)
AT (1) ATE298578T1 (de)
CA (1) CA2259520C (de)
DE (1) DE69733651T2 (de)
DK (1) DK0909562T3 (de)
ES (1) ES2242226T3 (de)
WO (1) WO1998001139A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7799198A (en) * 1997-05-23 1998-12-21 Eisai Co. Ltd. Method for preparing pharmaceutical formulation
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
WO2000003744A2 (en) * 1998-07-14 2000-01-27 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid a
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
WO2001060382A1 (en) * 2000-02-18 2001-08-23 Eisai Co., Ltd. Micelles
ES2377077T3 (es) 2000-10-18 2012-03-22 Glaxosmithkline Biologicals S.A. Vacunas que comprenden al antígeno MAGE unido a un fragmento de proteína D
US7759323B2 (en) * 2001-05-22 2010-07-20 Eisai R & D Management Co., Ltd. Highly purified antiendotoxin compound
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
SI2068918T1 (sl) 2006-09-26 2012-09-28 Infectious Disease Res Inst Si - ep sestavek za cepljenje, ki vsebuje sintetiäśna pomagala
WO2009155489A2 (en) 2008-06-19 2009-12-23 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
RU2732574C2 (ru) 2009-06-05 2020-09-21 Инфекшес Дизиз Рисерч Инститьют Синтетические глюкопиранозиллипидные адъюванты
AU2010270722B2 (en) 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
WO2012006367A2 (en) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
WO2012097346A1 (en) 2011-01-13 2012-07-19 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
BR112013018074A2 (pt) 2011-01-13 2020-12-01 Variation Biotechnologies, Inc. métodos para a preparação de vesículas e formulações produzidas a partir dessas
CA2832307A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
EP2802353A4 (de) 2012-01-12 2015-12-02 Variation Biotechnologies Inc Zusammensetzungen und verfahren zur behandlung von virusinfektionen
RU2698906C2 (ru) 2012-01-27 2019-09-02 Вэриэйшн Биотекнолоджиз, Инк. Способы и композиции для терапевтических агентов
NZ701881A (en) 2012-05-16 2016-10-28 Immune Design Corp Vaccines for hsv-2
AU2014253791B2 (en) 2013-04-18 2019-05-02 Immune Design Corp. GLA monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
CN107531736B (zh) 2015-01-06 2022-04-15 免疫疫苗科技公司 脂质a模拟物、其制备方法和用途
AU2018330165A1 (en) 2017-09-08 2020-04-02 Access To Advanced Health Institute Liposomal formulations comprising saponin and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1216686B (it) * 1988-04-01 1990-03-08 Chiesi Farma Spa Formulazioni farmaceutiche acquose di piroxicam e procedimento per laloro preparazione.
JPH04198192A (ja) * 1990-11-28 1992-07-17 Japan Tobacco Inc リピッドａ類縁体の水溶液
US5530113A (en) * 1991-10-11 1996-06-25 Eisai Co., Ltd. Anti-endotoxin compounds
AU660325B2 (en) * 1991-10-11 1995-06-22 Eisai Co. Ltd. Anti-endotoxin compounds and related molecules and methods
US5681824A (en) * 1995-06-05 1997-10-28 Eisai Co., Ltd. Substituted liposaccharides useful in the treatment and prevention of endotoxemia

Also Published As

Publication number Publication date
CA2259520C (en) 2007-09-11
ES2242226T3 (es) 2005-11-01
EP0909562A1 (de) 1999-04-21
WO1998001139A1 (en) 1998-01-15
CN1150001C (zh) 2004-05-19
DE69733651D1 (de) 2005-08-04
US6235724B1 (en) 2001-05-22
CA2259520A1 (en) 1998-01-15
EP0909562A4 (de) 1999-12-29
DK0909562T3 (da) 2005-08-22
CN1224355A (zh) 1999-07-28
DE69733651T2 (de) 2006-05-18
EP0909562B1 (de) 2005-06-29

Similar Documents

Publication Publication Date Title
ATE298578T1 (de) Lipid a-analoge enthaltende injektionen und verfahren zu deren herstellung
ATE334136T1 (de) Verfahren zur herstellung von azithromycin
DE68923805D1 (de) Verfahren zur herstellung von optisch aktivem 1,3-butanediol.
DE69006290D1 (de) N-Substituierte Benzyloxyiminderivate, Verfahren zu deren Herstellung und deren Verwendung.
ATE285754T1 (de) Pharmazeutische zusammensetzung mit lyophilisierten lyposomen welche einen unlöslichen aktiven wirkstoff einschliessen, verfahren zu dessen herstellung
ATE293595T1 (de) Thyroidhormon-analoga und verfahren zu ihrer herstellung
DE3872620D1 (de) (arylsulphonyl)-nitromethane, verfahren zu deren herstellung und deren verwendung in pharmazeutischen zusammensetzungen.
PT91302A (pt) Processo para a preparacao de composicoes farmaceuticas contendo imidazo {2,1-a} isoquinolinas substituidas por 5-heteroarilo ou 5-arilo
DE58902890D1 (de) Verfahren zur herstellung von 2,5-diarylaminoterephthalsaeuren.
DE58905117D1 (de) Verfahren zur herstellung von 4-chlor-2,5-dimethoxyanilin.
DE59001106D1 (de) Verfahren zur herstellung von 1,1,1-trifluor-2-chlorethan.
DE68912809D1 (de) Verfahren zur Herstellung von Bis(2,2,6,6-tetramethyl-4-piperidyl)amin.
DE68917322D1 (de) Motorlagerlegierung und verfahren zu deren herstellung.
DE58904175D1 (de) Verfahren zur herstellung von 4,4'-dihalogeno-biphenylen.
DE69130215D1 (de) Verfahren zur herstellung von hexahydropyridazin-1,2-dicarbonsäurederivaten
DE58906758D1 (de) Verfahren zur Herstellung eines faseroptischen Sternkopplers und nach diesem Verfahren hergestellter faseroptischer Sternkoppler.
DE68907180D1 (de) Verfahren zur herstellung von 2,3,5-trimethylbenzochinon.
DE59005479D1 (de) Verfahren zur herstellung von chinophthalonderivaten.
DE59000677D1 (de) Verfahren zur herstellung von 2-cyan-3,3-diarylacrylsaeureestern.
ATE128113T1 (de) Calicheamicinon, dessen abkömmlinge und analogen und verfahren zu deren herstellung.
DE69605443D1 (de) Umweltverträgliche, wässrige mullit-sole, mullit-zusammensetzungen und verfahren zu deren herstellung
DE58904614D1 (de) Verfahren zur herstellung von 1,1,2-trialkoxyethanen.
DE59002140D1 (de) Verfahren zur herstellung von 2,3,5-trimethyl-p-benzochinon.
DE3880988D1 (de) Cinnolin-derivate, verfahren zu deren herstellung und diese enthaltende herbizide zusammenstellungen.
DE3768617D1 (de) Verfahren zur herstellung von 2,4-diamino-3-oxy-pyrimidin-derivaten.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0909562

Country of ref document: EP

EEIH Change in the person of patent owner